logo-loader
viewMotif Bio PLC

Motif Bio Plc keen to make its 'best shot at goal' with iclaprim NDA

Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB, NASDAQ:MTFB), tells Proactive Investors they're taking some additional time over the new drug application (NDA) for iclaprim as they're keen to make the strongest possible submission to the US regulator.

The next-generation antibiotic has been developed initially to treat acute bacterial skin and skin structure infections and has successfully negotiated two phase III clinical trials.

Quick facts: Motif Bio PLC

Price: 0.67 GBX

AIM:MTFB
Market: AIM
Market Cap: £2.29 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Motif Bio announces US FDA approval deadline for its antibiotic drug

Motif Bio (LON:MTFB, NASDAQ: MTFB) CEO Graham Lumsden tells Proactive Investors the US FDA has begun the process of assessing whether the company’s next-generation antibiotic should be allowed to go on sale in the US. Motif's drug iclaprim has been granted a priority review by the...

on 08/15/2018

RNS

Second Price Monitoring Extn

1 week, 4 days ago

Price Monitoring Extension

1 week, 4 days ago

Change of Adviser

1 week, 4 days ago

Conditional Placing

1 week, 5 days ago

Half-year Report

2 weeks ago

2 min read